Modulight Bio

Executive Summary

Modulight Bio is an Israeli preclinical-stage biotech developing a precision neuromodulation platform that combines gene-therapy delivery of a novel bistable inhibitory GPCR opsin (eOPN3) with implantable light devices. This optogenetic approach enables light-controlled, reversible silencing of overactive neural circuits, targeting severe neurological disorders including trigeminal neuropathic pain, drug-resistant epilepsy, and movement disorders. The company's technology aims to provide rapid symptom relief without the side effects associated with traditional pharmacological or electrical stimulation therapies. Founded in 2020, Modulight has raised $12 million to advance its platform toward the clinic. Key upcoming milestones include completion of IND-enabling studies, securing Series A financing, and potential early clinical trial initiation. The emerging field of optogenetics for neurological disorders presents a significant opportunity, though the company remains at an early stage with substantial technical and regulatory hurdles. Modulight's differentiated approach and experienced team position it well within the competitive landscape, but investors should note the long development timeline and capital requirements typical of preclinical gene-therapy programs.

Upcoming Catalysts (preview)

• Q1 2026Series A Financing Close70% success
• Q4 2026IND/CTA Filing for Lead Indication (Trigeminal Neuropathic Pain)40% success
• Q2 2027First-in-Human Clinical Trial Initiation30% success